Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study symbols : Snynf save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.35 -9.27% -10.21% 16K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph6501 first study
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $145.23 -1.02% -1.03% 500K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
opl-0401 health treatment study diabetic
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Published: 2024-03-01 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -0.43%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
ibi3002 first australia study
Global mRNA-based Vaccines and Therapeutics Market is Projected to Grow Immensely During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-25 (Crawled : 23:00) - prnewswire.com
MTLHY | $29.93 -11.69% 1.1K
|
n/a
|
| O: -1.11%
H: 0.1%
C: 0.1%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.25%
H: 0.27%
C: -0.2%
SLN | $21.575 1.53% 1.51% 120K
|
Health Technology
|
| O: 4.32%
H: 0.0%
C: -3.68%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 0.72%
H: 0.34%
C: -1.68%
MRUS | $41.01 1.74% 1.71% 410K
|
Health Technology
|
| O: 0.35%
H: 2.81%
C: -0.53%
ICLR | $291.85 -0.74% -0.75% 390K
|
Health Technology
|
| O: 1.13%
H: 0.82%
C: -0.74%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -1.35%
H: 0.12%
C: -0.83%
global therapeutics study market
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
RGNX | News | $17.01 -2.8% -2.88% 410K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
ADVM | $11.32 -2.5% -2.56% 68K
|
Health Technology
|
| O: -0.69%
H: 2.32%
C: -0.12%
therapy growth study market
Sjogren's Syndrome Market to Register Sustainable Growth During the Study Period (2019-2032), Predicts DelveInsight | Key Players - Horizon Therapeutics, Dompe Farmaceutici, MorphoSys, Resolve Therapeutics, Novartis, Johnson & Johnson
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: -8.42%
resolve key growth study market
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published: 2024-01-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.02%
H: 0.41%
C: 0.41%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.43%
H: 2.12%
C: 2.03%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.64%
H: 4.97%
C: 4.9%
ibi362 obesity first chinese study
Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.21%
H: 0.63%
C: 0.1%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
cancer growth study market
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN | $28.97 -1.56% -1.59% 390K
|
Health Technology
|
| O: -0.11%
H: 0.82%
C: -2.31%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM | $69.69 1.28% 1.26% 400K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD | News | $17.2 0.7% 0.7% 1M
|
Health Technology
|
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics growth study market
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
UCBJY | $63.31 -4.38% 9.4K
|
Manufacturing
|
| O: -0.62%
H: 1.01%
C: 1.01%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
CPRX | $15.99 2.9% 2.81% 1.4M
|
Health Technology
|
| O: -0.37%
H: 5.49%
C: 5.49%
companies positive growth study market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight
Published: 2023-11-21 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
RCUS 4 | $14.84 -6.49% 0.0% 790K
|
Health Technology
|
| O: 1.88%
H: 0.92%
C: -1.42%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
drug cancer treatment show growth study market
Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici
Published: 2023-11-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 3.37%
H: 1.29%
C: 1.29%
NVO | News | $124.53 0.88% 0.0% 2.6M
|
Health Technology
|
| O: 2.62%
H: 0.67%
C: 0.58%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -3.12%
H: 0.61%
C: -0.46%
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -2.2%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.54%
H: 0.0%
C: 0.0%
companies diabetes study market
More than two in three people with diabetes already have complications at diagnosis, International Diabetes Federation study finds
Published: 2023-11-14 (Crawled : 00:00) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
international diabetes study
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
Published: 2023-11-06 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
TXG | $29.12 -5.46% -5.77% 2.9M
|
Health Technology
|
| O: -0.98%
H: 3.21%
C: 1.96%
genomics study
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.94%
H: 2.55%
C: 2.55%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -4.18%
H: 0.49%
C: -0.02%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
CALT | $18.8 5.62% 5.32% 6.8K
|
Health Technology
|
| O: -2.27%
H: 2.01%
C: 0.44%
study market
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.